TAF4: A Potential Drug Target and Biomarker for Transcription Initiation

Target Name: TAF4

NCBI ID: G6874

TAF4

TAF4: A Potential Drug Target and Biomarker for Transcription Initiation

Abstract: TAF4, the 130 kDa subunit of the Transcription Initiation Factor TFIID, is a critical protein for the regulation of gene expression. Dependence on TAF4 has been implicated in various diseases, including cancer, neurodegenerative disorders, and chronic diseases. This article aims to provide an overview of TAF4, its functions, and potential as a drug target and biomarker.

Introduction:
Transcription Initiation Factor TFIID (TAF) is a protein that plays a crucial role in the regulation of gene expression. It is a highly conserved protein that is present in various cell types and is involved in the process of transcription initiation, which is the first step in the gene expression pathway. TAF4 is one of the subunits of TFIID and is responsible for the N-terminal domain of the protein. The N-terminal domain is critical for the interaction with various DNA-binding factors, which are essential for the initiation of transcription.

TAF4 functions as a transcription factor that regulates gene expression by binding to specific DNA-binding factors. It plays a vital role in the regulation of cell cycle progression, apoptosis, and DNA replication. TAF4 has been implicated in various diseases, including cancer, neurodegenerative disorders, and chronic diseases.

Potential as a drug target:
The potential of TAF4 as a drug target is high due to its various functions in disease progression. TAF4 has been shown to be involved in the regulation of cell proliferation, apoptosis, and translation, which are crucial processes for the development and progression of various diseases.

One of the potential mechanisms by which TAF4 can be targeted as a drug is its role in the regulation of cell proliferation. TAF4 has been shown to play a vital role in the regulation of cell cycle progression, and alterations in TAF4 levels or activity have been implicated in the development of various cancers, including breast, ovarian, and colorectal cancers. Therefore, inhibitors of TAF4 have been shown to be effective in treating various cancers.

Another potential mechanism by which TAF4 can be targeted as a drug is its role in the regulation of apoptosis. TAF4 has been shown to play a vital role in the regulation of apoptosis, which is a natural process that helps eliminate damaged or dysfunctional cells. Alterations in TAF4 levels or activity have been implicated in the regulation of apoptosis, and therefore, inhibitors of TAF4 have been shown to be effective in treating various neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

Potential as a biomarker:
TAF4 has also been shown to be a potential biomarker for various diseases. The levels of TAF4 have been shown to be altered in various diseases, including cancer, neurodegenerative disorders, and chronic diseases. Therefore, TAF4 can be used as a biomarker for these diseases..

Conclusion:
In conclusion, TAF4 is a protein that plays a crucial role in the regulation of gene expression and has been implicated in various diseases. Its potential as a drug target and biomarker makes it an attractive target for research in the field of therapeutic agents. Further studies are needed to fully understand the functions of TAF4 and its potential as a drug target and biomarker.

Protein Name: TATA-box Binding Protein Associated Factor 4

Functions: The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473, PubMed:10594036, PubMed:8942982). TAF4 may maintain an association between the TFIID and TFIIA complexes, while bound to the promoter, together with TBP, during PIC assembly (PubMed:33795473). Potentiates transcriptional activation by the AF-2S of the retinoic acid, vitamin D3 and thyroid hormone (PubMed:9192867)

The "TAF4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets